SCIENTIFIC PROGRAM

Thursday 12

12.00	Allergan Symposium
	Evaluating the impact of Botox® from movement disorders to enhancing aesthetics
Chairs	M.F. Brin (Irvine, CA, USA)
12.00	M.F. Brin (Irvine, CA, USA)	Opening remarks
12.15	J.-M. Gracies (Paris, France)	First steps in movement disorders
12.45	M. de Maio (San Paulo, Brasil)	Enhancing aesthetics
13.15	Panel discussion
	M.F. Brin (Irvine, CA, USA)	Chairmen’s closing remarks
13.45	Closure of Symposium
Plenary session 1
Chairs	C. Montecucco (Padua, Italy), M. Hallett (Bethesda, MD, USA)
14.00	J. Molgo (Gif-sur-Yvette, France)	Multiple events triggered by the use of botulinum neurotoxins at the vertebrate neuromuscular junction
14.45	D. M. Simpson (New York, NY, USA)	Motor disorders: evidence-based review of the use of botulinum toxins
15.30	C O F F E E B R E A K
Plenary session 2
Chairs:	G. Schiavo (London, UK), A. Albanese (Milan, Italy)
16.00	A. Brunger (Stanford, CA, USA)	Botulinum neurotoxin interactions with substrate
16.30	O. Dolly (Dublin, Ireland)	Chimeras of botulinum neurotoxins give insights into the inhibitory patterns of exocytosis by serotypes
17.00	A. Rummel (Hannover, Germany)	Characterising and exploiting the binding of botulinum neurotoxins to their neuronal receptors
17.30	J. Jankovic (Houston, TX, USA)	Disease-oriented approach to botulinum toxin use
18.00	Eisai/Solstice Symposium
	Botulinum Neurotoxin B (Neurobloc®): new developments in managing cervical dystonia
Chairs	A. Albanese (Milan, Italy), P. Moore (Liverpool, UK)
18.15	A.Albanese (Milan, Italy)	Welcome and introduction
18.25	P. Moore (Liverpool, UK)	NeuroBloc® in the management of cervical dystonia: what is the current evidence?
19.10	P. Ganju (London, UK)	NeuroBloc® website: an online learning tool for clinicians and information source for cervical dystonia patients
19.30	Discussion
19.40	P. Moore (Liverpool, UK)	Summary and close
20.00	O P E N I N G C E R E M O N Y
20.30	W E L C O M E R E C E P T I O N
Friday 13
Plenary session 3
Chairs:	H. Bigalke (Hannover, Germany), K. Foster (Abingdon, UK)
08.30	R. Jahn (Gottingen, Germany)	Synaptic vesicle cycle
09.15	M. Naumann (Augsburg, Germany)	Evidence-based review of the safety and efficacy of botulinum neurotoxin in the treatment of autonomic and urologic disorders, and pain
10.00	M. Montal (San Diego, CA, USA)	Translocation of the light chain protease by the heavy chain protein-conducting channel
10.45	C O F F E E B R E A K
Plenary session 4
Chairs:	J. Jankovic (Houston, TX, USA), A. Berardelli (Rome, Italy)
11.15	Z. Atassi (Houston, TX, USA)	Immune recognition of BoNTs A and B: how anti-toxin antibodies obstruct toxin action
12.00	D. Dressler (Rostock, Germany)	Primary and secondary resistance to botulinum toxin treatment
12.30	E.A. Johnson (Madison, WI, USA)	A neuronal cell-based assay for highly sensitive detection of pharmaceutical preparations of BoNT/A and patient neutralizing serum antibodies
13.00	L U N C H
14.30	Poster viewing with authors standing
Plenary session 5
Chairs:	M. Hallett (Bethesda, MD, USA), G. Schiavo (London, UK)
15.30	M. Caleo (Pisa, Italy)	Central effects of botulinum neurotoxins
16.00	O. Dolly (Dublin, Ireland)	Discussion facilitator
16.30	C O F F E E B R E A K
Parallel Session - Dystonia
Chairs:	M. Hallett (Bethesda, MD, USA), A.R. Bentivoglio (Rome, Italy)
17.00	A. Blitzer (New York, NY, USA)	Botulinum toxin therapy for laryngeal dystonia and other hyperfunctional laryngeal disorders
17.30	R. Benecke (Rostock, Germany)	Botulinum toxins for treatment of cranial dystonia
18.00	C. Comella (Chicago, IL, USA)	Botulinum toxins for the treatment of cervical dystonia
18.30	M. Hallett (Bethesda, MD, USA)	Focal hand dystonia
Parallel Session - Autonomic and other applications
Chairs:	C. Smith (Houston, TX, USA), M. Porta (Milan, Italy)
17.00	C. Smith (Houston, TX, USA)	GU indications: overactive bladder, benign prostatic hyperplasia, and interstitial cystitis
17.30	J.A. Abbott (Sidney, Australia)	Botulinum toxin for pelvic floor dysfunction
18.00	DA Glaser (St. Louis, MO, USA)	Cosmetic applications and hyperhidrosis
18.30	C.H. Adler (Scottsdale, AZ, USA)	Perioperative use of botulinum toxins
Parallel Session - Structure and function A
Chairs:	T. Binz (Hannover, Germany), C. Montecucco (Padua, Italy)
17.00	G. Schiavo (London, UK)	The mechanism of axonal transport of tetanus toxin in vivo and in vitro
17.30	K.D. Janda (La Jolla, CA, USA)	Small molecule therapeutic approaches for the treatment of botulinum neurotoxins A and B Intoxication
18.00	J.D. Marks (San Francisco, CA, USA)	Recombinant antibody potently neutralizes types A, B, and E botulinum neurotoxins by a clearance driven mechanism
18.30	K. Foster (Abingdon, UK)	Engineered toxins: new therapeutics
19.00	Closure of scientific sessions
19.30	Allergan Symposium
	Spasticity debate: this house believes that spasticity is an acute issue
Chairs:	A. Berardelli (Rome, Italy), F. Molteni (Costamasnaga, Italy)
19.30	A. Berardelli (Rome, Italy)	Opening remarks
19.45	A.B. Ward (Stoke-on-Trent, UK)	Proposing the motion
20.05	A Esquenazi (Philadelphia, PA, USA)	Opposing the motion
20.25	Debate open to the floor
20.50	F. Molteni (Costamasnaga, Italy)	Closing remarks
21.30	Closure of Symposium
Saturday 14
Plenary session 6
Chairs:	M. Hallett (Bethesda, MD, USA), G. Bussone (Milan, Italy)
8.30	P. Reeh (Nuremberg, Germany)	Neuropeptide release from nociceptors: a potential dug target
9.15	S. Silberstein (Philadelphia, PA, USA)	Headaches, migraine, and botulinum toxins
10.00	C O F F E E B R E A K
What unique properties differentiate the various botulinum toxin products?
Chairs:	J. Jankovic (Houston, TX, USA), M. Hallett (Bethesda, MD, USA), A. Albanese (Milan, Italy)
10.30	R. Aoki (Irvine, CA, USA)	Botox®
11.00	A. Pickett (Wrexham, UK)	Dysport®: Pharmacological properties and factors that influence toxin action
11.30	J. Arezzo (Bronx, NY, USA)	NeuroBloc® / Myobloc®: unique features and findings
12.00	J. Frevert (Potsdam, Germany)	Xeomin® is free from complexing proteins
12.30	General discussion of toxin products
13.00	R. Kaji (Tokushima, Japan)	Experience with A2NTX on dystonia and spasticity
13.30	L U N C H
14.30	Poster viewing with authors standing
16.30	B R E A K
Parallel Session - Spasticity and other movement disorders
Chairs:	A. Esquenazi (Philadelphia, PA, USA), F. Molteni (Costamasnaga, Italy)
17.00	A. Esquenazi (Philadelphia, PA, USA)	Patient registry of outcomes in spasticity care
17.30	A. Albanese (Milan, Italy)	Adult upper limb spasticity
18.00	K. Graham (Melbourne, Australia)	Safety of botulinum toxin A in cerebral palsy
18.30	G. Defazio (Bari, Italy)	Tics, tremors and other hyperkinesias
Parallel Session - Pain syndromes and future developments
Chairs:	S. Silberstein (Philadelphia, PA, USA), H. Bigalke (Hannover, Germany)
17.00	R. Burstein (Cambridge, MA, USA)	Success and failure of preventative migraine treatment with Botulinum Toxin Type A: Association with a novel classification of migraine headache
17.30	M.L. Mahowald (Minneapolis, MN, USA)	Intra-articular botulinum Toxin A for osteoarticular pain
18.00	B. Jabbari (New Haven, CT, USA)	Botulinum toxin treatment of low back pain and fibromyalgia
18.30	M. Brin (Irvine, CA, USA)	Future Indications for Botulinum Toxin (BoNT)
Parallel Session - Structure and function B
Chairs:	M. Montal (San Diego, CA, USA), T. Binz (Hannover, Germany)
17.00	Y. Fujinaga (Osaka, Japan)	A novel function of botulinum toxin-associated proteins: the HA component disrupts intestinal epithelial intercellular junctions to increase toxin absorption
17.30	J. Barbieri (Milwaukee, WI, USA)	Association of botulinum neurotoxins with synaptic vesicle protein complexes
18.00	M. Matteoli (Milan, Italy)	Studies with botulinum toxins in excitatory and inhibitory neurons
18.30	C. Montecucco (Padua, Italy)	The entry of botulinum neurotoxins and snake presynaptic neurotoxins into nerve terminals
19.00	Closure of scientific sessions
20.00	G A L A D I N N E R

Updated: May 27th, 2008